July 29, 2024
Journal of Investigative Dermatology: Interleukin 1 Receptor–Associated Kinase 4 is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers
Alice McDonald, et al.
Hidradenitis Suppurativa (HS)
Read More
November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
August 16, 2023
Discovery of KT-474, a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases
American Chemical Society (ACS) Fall 2023 Meeting
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
May 18, 2023
Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis
European Academy of Dermatology & Venereology (EADV) Symposium 2023
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 26, 2022
The Phase 1 Healthy Volunteer Clinical Trial of KT-474
5th Annual Targeted Protein Degradation (TPD) Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 26, 2022
Development and Performance of Pharmacodynamic Assays to Demonstrate Proof-of-Mechanism for IRAK4 Degraders in a Phase1 Study
5th Annual Targeted Protein Degradation (TPD) Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
July 28, 2022
Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases
3rd B&T Cell-Mediated Autoimmune Disease Drug Development
Read More
May 17, 2022
Kinetics of IRAK4 Degradation and Impact on Functional Response in Circulating Immune Cells and Skin Cell Subsets
Society for Investigative Dermatology (SID) 2022 Annual Meeting
Read More
May 3, 2022
Selective IRAK4 Degradation, Not Kinase Inhibition, Blocks TLR-activated NF-kB and p38 Signaling Leading to broad Cytokine Inhibition
The American Association of Immunologists (AAI) Immunology2022(TM)
Read More